Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Intranasal administration of OM-85, a bacterial lysate, alters lung transcriptional profiles and protects against experimental asthma

ABSTRACT: Intranasal administration of OM-85, a bacterial lysate, alters lung transcriptional profiles and protects against experimental asthma

PROVIDER: PRJNA705359 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Intranasal administration of OM-85, a bacterial lysate, alters lung transcriptional profiles and protects against experimental asthma

Project description:Background: Microbial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections, and a clinical trial is testing its ability to prevent asthma in at-risk children. On the other hand, we previously showed that intra-nasal administration of products from microbe-rich farm environments abrogate experimental allergic asthma. Objectives: To investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma, and to identify protective cellular and molecular mechanisms activated through this natural route. Methods: BALB/cJ mice (7-8 weeks old) sensitized and challenged with Ovalbumin received OM-85 intra-nasally, and cardinal cellular and molecular asthma phenotypes were measured. Murine lung gene expression was profiled by RNA-sequencing. Results: Airway administration of OM-85 suppressed allergic asthma and altered the transcriptome profile in unfractionated lung tissue. Conclusion We provide the first demonstration that administration of a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways.

2021-10-19 | GSE167867 | GEO

Gene expression profile of human mono-derived DCs stimulated with the bacterial lysate OM-85

Project description:OM-85 is a bacterial lysate used in clinical practice to reduce duration and frequency of recurrent respiratory tract infections. Whereas knowledge on its regulatory effects in vivo has substantially advanced, the mechanisms of OM-85 sensing remain inadequately addressed.The purpose of this study was to investigate the transptomic profile of human mo-DCs after ex vivo stimulation with OM-85 at determine to what extent OM-85-induced gene signature in different myeloid cell subsets is dependent on TLR2/TLR4 expression. We also aimed to compare the OM-85-triggered gene signature with the signatures induced by specific TLR2 or TLR4 agonists.

2024-03-11 | GSE260787 | GEO

Gene exprssion at single cell level in patients broncoalveolar lavage (BAL) cells stimulated ex vivo with bacterial lysate OM-85

Project description:OM-85 is a bacterial lysate used in clinical practice to reduce duration and frequency of recurrent respiratory tract infections. Whereas knowledge on its regulatory effects in vivo has substantially advanced, the mechanisms of OM-85 sensing remain inadequately addressed.The purpose of this study was to investigate the transptomic profile of human airway immune cells in the BAL after ex vivo stimulation with OM-85 at the single cell level and determine to what extent OM-85-induced gene signature in different myeloid cell subsets is dependent on TLR2/TLR4 expression.

2024-03-16 | GSE261353 | GEO

Adjuvant treatment with the bacterial lysate (OM-85) improves management of atopic dermatitis: A randomized study.

Project description: Not available

| S-EPMC5363804 | biostudies-literature

Use of the Bacterial Lysate OM-85 in the Paediatric Population in Italy: A Retrospective Cohort Study.

Project description: Not available

| S-EPMC8297025 | biostudies-literature

The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression.

Project description: Not available

| S-EPMC8660661 | biostudies-literature

OM-85 Broncho-Vaxom<sup>®</sup>, a Bacterial Lysate, Reduces SARS-CoV-2 Binding Proteins on Human Bronchial Epithelial Cells.

Project description: Not available

| S-EPMC8615539 | biostudies-literature

single cell RNA sequencing of migratory dendritic cells after intranasal adjuvant/tolerogen administration

Project description:We compared migratory DCs in draining mediastinal lymph node after intranasal administration of different vaccine adjuvants based on CTA1 subunit of cholera toxin. The goal was to determine different characteristics of dendritic cells subsets after pro-inflammatory vs tolerogenic adjuvant. We had 3 groups: CTA1-DD (pro- inflammatory), CTA1(R7K)-DD (tolerogenic) and PBS to define DC which migrate to LN. All vaccine constructs included 3Ea peptide to allow for sorting of DC which took up the vaccine.

2023-05-15 | E-MTAB-12942 | biostudies-arrayexpress

Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models

Project description:Intranasal vaccines can prime or recruit to the respiratory epithelium mucosal immune cells capable of preventing transmission of SARS-CoV-2. We found that a single intranasal dose of serotype 5-based adenoviral vectors expressing either the receptor binding domain (Ad5-RBD) or the complete ectodomain (Ad5-S) of the SARS-CoV-2 spike protein was effective in inducing i) secretory and serum anti-spike IgA and IgG, ii) robust SARS-CoV-2-neutralizing activity in the serum and in respiratory secretions, iii) rigorous spike-directed T helper 1 cell/cytotoxic T cell immunity, and iv) protection of wild-type mice from a challenge with the SARS-CoV-2 beta variant. Our data confirm and extend previous studies reporting promising preclinical results on vector-based intranasal SARS-CoV-2 vaccination, and support the potential of this approach to elicit mucosal immunity for preventing reinfection and transmission of SARS-CoV-2 more effectively than the currently available vaccines.

2023-05-01 | GSE223476 | GEO

Transplacental Innate Immune Training via Maternal Microbial Exposure: Role of XBP1-ERN1 Axis in Dendritic Cell Precursor Programming

Project description:Background: Maternal enviromnetal exposures during pregnancy can transplacentally train the developing fetal immune system. We have proviously shown that treatment of pregnant mice with the microbial-derived OM-85 can protect their offspring against allergic airways disease. Purpose: To characterise the cellular/molecular mechanisms underpinning this protection, focusing on the fetal bone marrow as a potential mechanistic target. Methods: Pregnant mice were orally treated with OM-85 from gestation day (GD) 9.5-17.5. Fetal bone marrow and thymus was collected from OM-85 treated and non-treated mothers at GD18.5. Cellular and molecular profiles were characterised by multi-colour flow cytometry and transcriptomics (RNA-Seq) respectively.. Molecular profiling utilised upstream regulator analysis .Protein-level validation of upstream regulator analysis results was performed by multi-colour flow cytometry. Results: Maternal OM-85 treatment induces transplacental signals that manifest in fetal bone marrow as an enriched population of conventional dendric cells (cDC) displaying enhanced functional maturation. Moreover, the myeloid progenitor populations directly upstream of this cDC pool were significantly boosted in response to maternal treatment. Transcriptomic analysis of fetal bone marrow identified maternal OM-85-induced activation of X-box binding protein 1 (XBP1), with upregulation of active XBP1 localised to cDC precursors. Conclusions: Maternal OM-85 treatment during pregnancy transplacentally accelerates functional immunocompetence of fetal bone marrow cDCs and for the first time we identify the transcription factor XBP1 as a putative driver of this immune training mechanism.

2020-11-22 | GSE140143 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data